脂质代谢在肝硬化发生发展机制的研究进展
Research Progress on the Mechanism of Lipid Metabolism in the Occurrence and Development of Cirrhosis
DOI: 10.12677/tcm.2024.136177, PDF,   
作者: 王燕凤, 何广英：广西中医药大学研究生院，广西 南宁；胡振斌：广西中医药大学第一附属医院肝病科，广西 南宁
关键词: 肝硬化；脂质代谢；代谢相关脂肪性肝病；Liver Cirrhosis； Lipid Metabolism； Metabolism-Related Fatty Liver Disease
摘要: 肝硬化病因有多种，常见的病因主要有病毒性肝炎、自身免疫性肝病、酒精性肝病及代谢相关脂肪性肝病等。其中代谢相关脂肪性肝病所导致肝硬化比例逐渐增加，及相关研究人员的深入研究，越来越受到重视。本文讨论了脂质代谢与肝硬化发生的关系和作用机制，以及通过调控脂质代谢治疗肝硬化的国内外相关研究，旨在为临床防治肝硬化提供新的方向和进一步研究。
Abstract: There are many causes of liver cirrhosis. The common causes are viral hepatitis, autoimmune liver disease, alcoholic liver disease and metabolic related fatty liver disease. Among them, the proportion of cirrhosis caused by metabolism-related fatty liver disease has gradually increased, and the in-depth study of related researchers has received more and more attention. This article discusses the relationship and mechanism of lipid metabolism and cirrhosis, as well as the domestic and foreign related research on the treatment of cirrhosis by regulating lipid metabolism, aiming to provide a new direction and further research for clinical prevention and treatment of cirrhosis.
文章引用：王燕凤, 胡振斌, 何广英. 脂质代谢在肝硬化发生发展机制的研究进展[J]. 中医学, 2024, 13(6): 1171-1177. https://doi.org/10.12677/tcm.2024.136177

参考文献

[1] Mayasari, V.I. and Puspitasari, Y. (2023) Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome: Diagnostic and Laboratory Approach. Indonesian Journal of Clinical Pathology and Medical Laboratory, 29, 86-93. [Google Scholar] [CrossRef] 
[2] Berzigotti, A. and Abraldes, J.G. (2013) Impact of Obesity and Insulin-Resistance on Cirrhosis and Portal Hypertension. Gastroenterología y Hepatología, 36, 527-533. [Google Scholar] [CrossRef] [PubMed]
[3] Berzigotti, A., Albillos, A., Villanueva, C., Genescá, J., Ardevol, A., Augustín, S., Calleja, J.L., Bañares, R., García‐ Pagán, J.C., Mesonero, F., Bosch, J. and on behalf of the Ciberehd SportDiet Collaborative Group (2017) Effects of an Intensive Lifestyle Intervention Program on Portal Hypertension in Patients with Cirrhosis and Obesity: The SportDiet Study. Hepatology, 65, 1293-1305. [Google Scholar] [CrossRef] [PubMed]
[4] Parker, R., Kim, S.J., Im, G.Y., Nahas, J., Dhesi, B., Vergis, N., Sinha, A., Ghezzi, A., Rink, M.R., McCune, A., Aithal, G.P., Newsome, P.N., Weston, C.J., Holt, A. and Gao, B. (2019) Obesity in Acute Alcoholic Hepatitis Increases Morbidity and Mortality. eBioMedicine, 45, 511-518. [Google Scholar] [CrossRef] [PubMed]
[5] Roehlen, N., Crouchet, E. and Baumert, T.F. (2020) Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells, 9, Article 875. [Google Scholar] [CrossRef] [PubMed]
[6] Casati, S., Giannasi, C., Niada, S., Bergamaschi, R.F., Orioli, M. and Brini, A.T. (2021) Bioactive Lipids in MSCs Biology: State of the Art and Role in Inflammation. International Journal of Molecular Sciences, 22, Article 1481. [Google Scholar] [CrossRef] [PubMed]
[7] Bian, X., Liu, R., Meng, Y., Xing, D., Xu, D. and Lu, Z. (2020) Lipid Metabolism and Cancer. Journal of Experimental Medicine, 218, e20201606. [Google Scholar] [CrossRef] [PubMed]
[8] Abdel-Rahman, O. (2018) Statin Treatment and Outcomes of Metastatic Pancreatic Cancer: A Pooled Analysis of Two Phase III Studies. Clinical and Translational Oncology, 21, 810-816. [Google Scholar] [CrossRef] [PubMed]
[9] 翟晓君, 赵会颖, 杨萌, 张文亮, 李岚. 老年高血压患者脂质代谢异常与失眠关系研究[J]. 临床军医杂志, 2022, 50(9): 972-974.
[10] 赵冬梅, 夏志红, 苏惠娟. 血液透析联合血液灌流在维持性血液透析合并脂质代谢异常患者中的应用[J]. 海南医学, 2022, 33(13): 1646-1649.
[11] 贺润铖, 黄芷棋, 冯倩倩, 宁一博, 孙建宁, 张硕峰, 董世芬. 天山雪莲对老年脂质代谢异常(气虚血瘀型)小鼠的改善作用及机制研究[J]. 中草药, 2022, 53(17): 5433-5444.
[12] 宋峥, 苏文, 崔天盆, 郝建军, 徐辉甫, 明阳灿, 周秀莉. 中医体质辨识与脂质代谢异常冠心病关系研究[J]. 湖北中医杂志, 2022, 44(1): 43-46.
[13] Athyros, V.G., Doumas, M., Imprialos, K.P., Stavropoulos, K., Georgianou, E., Katsimardou, A. and Karagiannis, A. (2018) Diabetes and Lipid Metabolism. Hormones, 17, 61-67. [Google Scholar] [CrossRef] [PubMed]
[14] 闵冬雨, 刘勇明, 谢思梦, 梁元钰, 程美佳, 关雪, 鞠业涛, 王东妮, 陈民, 贾连群, 杨关林. 基于脂质代谢异常探析从痰论治阿尔茨海默病作用机理[J]. 中华中医药学刊, 2021, 39(9): 17-20.
[15] Jeon, S. and Carr, R. (2020) Alcohol Effects on Hepatic Lipid Metabolism. Journal of Lipid Research, 61, 470-479. [Google Scholar] [CrossRef] [PubMed]
[16] Pei, K., Gui, T., Kan, D., Feng, H., Jin, Y., Yang, Y., Zhang, Q., Du, Z., Gai, Z., Wu, J. and Li, Y. (2020) An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. BioMed Research International, 2020, Article ID: 4020249. [Google Scholar] [CrossRef] [PubMed]
[17] Sinha, R.A., Singh, B.K. and Yen, P.M. (2018) Direct Effects of Thyroid Hormones on Hepatic Lipid Metabolism. Nature Reviews Endocrinology, 14, 259-269. [Google Scholar] [CrossRef] [PubMed]
[18] 黄宝乐, 吴峰, 岳悦, 等. 甲亢患者血清miR-133a水平变化与甲状腺激素及脂质代谢的关联性研究[J]. 中国临床新医学, 2024, 17(3): 308-312.
[19] Alves-Bezerra, M. and Cohen, D.E. (2017) Triglyceride Metabolism in the Liver. Comprehensive Physiology, 8, 1-8.
[20] Mato, J.M., Alonso, C., Noureddin, M. and Lu, S.C. (2019) Biomarkers and Subtypes of Deranged Lipid Metabolism in Non-Alcoholic Fatty Liver Disease. World Journal of Gastroenterology, 25, 3009-3020. [Google Scholar] [CrossRef] [PubMed]
[21] Han, J. and Wang, Y. (2017) mTORC1 Signaling in Hepatic Lipid Metabolism. Protein & Cell, 9, 145-151. [Google Scholar] [CrossRef] [PubMed]
[22] Ma, Y., Chen, G., Yi, J., Li, Q., Tan, Z., Fan, W., Luo, X., He, Z., Si, Z. and Li, J. (2022) IRX3 Plays an Important Role in the Pathogenesis of Metabolic-Associated Fatty Liver Disease by Regulating Hepatic Lipid Metabolism. Frontiers in Endocrinology, 13, Article 895593. [Google Scholar] [CrossRef] [PubMed]
[23] Morigny, P., Boucher, J., Arner, P. and Langin, D. (2021) Lipid and Glucose Metabolism in White Adipocytes: Pathways, Dysfunction and Therapeutics. Nature Reviews Endocrinology, 17, 276-295. [Google Scholar] [CrossRef] [PubMed]
[24] Fan, L., Lai, R., Ma, N., Dong, Y., Li, Y., Wu, Q., Qiao, J., Lu, H., Gong, L., Tao, Z., Chen, J., Xie, Q. and Ren, J. (2021) miR-552-3p Modulates Transcriptional Activities of FXR and LXR to Ameliorate Hepatic Glycolipid Metabolism Disorder. Journal of Hepatology, 74, 8-19. [Google Scholar] [CrossRef] [PubMed]
[25] 中华医学会肝病学分会. 肝硬化诊治指南[J]. 中华肝脏病杂志, 2019, 27(11): 846-865.
[26] 李宝华, 何聪. 安络化纤丸联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效及作用机制[J]. 中药材, 2022, 45(10): 2512-2515.
[27] 苏园园, 黄诚山, 王海. 扶正化瘀胶囊联合恩替卡韦对乙型肝炎肝硬化患者肝纤维化及肝功能指标的影响[J]. 中国医药科学, 2022, 12(7): 106-109.
[28] 姚海娟, 陈鸿鑫, 李宏宇. 复方鳖甲软肝片防治肝纤维化的研究进展[J]. 中国冶金工业医学杂志, 2022, 39(3): 261-263.
[29] Eslam, M., Newsome, P.N., Sarin, S.K., Anstee, Q.M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J., Schattenberg, J.M., Kawaguchi, T., Arrese, M., Valenti, L., Shiha, G., Tiribelli, C., Yki-Järvinen, H., Fan, J., Grønbæk, H., Yilmaz, Y., Cortez-Pinto, H., Oliveira, C.P., Bedossa, P., Adams, L.A., Zheng, M., Fouad, Y., Chan, W., Mendez-Sanchez, N., Ahn, S.H., Castera, L., Bugianesi, E., Ratziu, V. and George, J. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209. [Google Scholar] [CrossRef] [PubMed]
[30] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版) [J]. 传染病信息, 2018, 31(5): 393-402, 420.
[31] Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R., Hazlehurst, J.M., Guo, K., Abouda, G., Aldersley, M.A., Stocken, D., Gough, S.C., Tomlinson, J.W., Brown, R.M., Hübscher, S.G. and Newsome, P.N. (2016) Liraglutide Safety and Efficacy in Patients with Non-Alcoholic Steatohepatitis (LEAN): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Study. The Lancet, 387, 679-690. [Google Scholar] [CrossRef] [PubMed]
[32] Argo, C.K., Patrie, J.T., Lackner, C., Henry, T.D., de Lange, E.E., Weltman, A.L., Shah, N.L., Al-Osaimi, A.M., Pramoonjago, P., Jayakumar, S., Binder, L.P., Simmons-Egolf, W.D., Burks, S.G., Bao, Y., Taylor, A.G., Rodriguez, J. and Caldwell, S.H. (2015) Effects of N-3 Fish Oil on Metabolic and Histological Parameters in NASH: A Double-Blind, Randomized, Placebo-Controlled Trial. Journal of Hepatology, 62, 190-197. [Google Scholar] [CrossRef] [PubMed]
[33] Lee, N.Y. and Suk, K.T. (2020) The Role of the Gut Microbiome in Liver Cirrhosis Treatment. International Journal of Molecular Sciences, 22, Article 199. [Google Scholar] [CrossRef] [PubMed]
[34] Campion, D., Giovo, I., Ponzo, P., Saracco, G.M., Balzola, F. and Alessandria, C. (2019) Dietary Approach and Gut Microbiota Modulation for Chronic Hepatic Encephalopathy in Cirrhosis. World Journal of Hepatology, 11, 489-512. [Google Scholar] [CrossRef] [PubMed]
[35] Hu, C., Zhao, L., Tao, J. and Li, L. (2019) Protective Role of Melatonin in Early‐Stage and End‐Stage Liver Cirrhosis. Journal of Cellular and Molecular Medicine, 23, 7151-7162. [Google Scholar] [CrossRef] [PubMed]
[36] Campos-Murguía, A., Ruiz-Margáin, A., González-Regueiro, J.A. and Macías-Rodríguez, R.U. (2020) Clinical Assessment and Management of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. World Journal of Gastroenterology, 26, 5919-5943. [Google Scholar] [CrossRef] [PubMed]